We came across a bullish thesis on Biogen Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on BIIB. Biogen Inc.'s share was trading at $143.81 as of September 18th. BIIB’s trailing and forward P/E were 13.86 and 9.04 respectively according to Yahoo Finance. create jobs 51/Shutterstock.com Biogen (BIIB) enters its July 31 Q2 earnings with investor focus on the rollout of its Alzheimer’s drug lecanemab and the durability of its multiple sclerosis franchise. T ...

Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc. (NASDAQ:BIIB) announced that it had finalized a deal to acquire Alcyone Therapeutics for an initial cash payment of $85 million and milestone payments. The acquisition focuses on the ThecaFlex DRx, an implantable subcutaneous port and catheter device that is being researched for antisense oligonucleotide (ASO) intrathecal delivery. The system is intended to give patients with neurological ill ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying FCX stock? Here’s what analysts think: Photo via ShutterstockLoading...Loading... ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying BIIB stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Question-and-Answer SessionPriya SinghalExecutive VP & Head of Development Yes, we've been very excited to create the new Biogen. And I'm really pleased because I think we are well on our way. And I'll start with the fact that from a commercial perspective, the Alzheimer's launch, we are seeing some inflection points in the LEQEMBI launch. This is important because we just got approval for subcutaneous maintenance, which we think is a very important option for patients. And we've also begun our rolling subm ...

Key Takeaways Biogen got an FDA CRL for its sNDA seeking approval of a higher-dose regimen of Spinraza.The FDA requested CMC updates, with no deficiencies flagged in clinical data for the higher dose.EMA and other regulators are reviewing filings, and Japan has already approved the higher dose.Biogen (BIIB) announced that the FDA has issued a complete response letter (CRL) to its supplemental new drug application (sNDA) seeking label expansion for a higher dose of its renowned spinal muscular atrophy (SMA) ...

Biogen (NasdaqGS:BIIB) FY Conference September 24, 2025 11:20 AM ET Company ParticipantsPriya Singhal - EVP & Head - DevelopmentConference Call ParticipantsWilliam Pickering - Senior AnalystWilliam PickeringIn many ways, I think that Biogen needs no introduction. It's a long, well-known company in our industry. Maybe you could take a few moments to speak to the journey that you've been on to create a new Biogen and how your approach to R&D is evolving.Priya SinghalYes, we've been very excited to create the ...

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild de ...

Biogen (NASDAQ:BIIB) reported that the U.S. FDA has declined to accept its request for a supplemental marketing authorization for a higher dose of Spinraza (nusinersen), a treatment for spinal muscular atrophy. The agency's complete response letter indicated that Biogen needs ...

The U.S. Food and Drug Administration has declined to approve a higher dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, dealing a setback to the compa... ...